Cerenome completes enrollment in Phase 2 Respect-GBM trial of Reyobiq in recurrent glioblastoma
CNSY•Cerenome completed enrollment in its Phase 2 Respect-GBM trial of Reyobiq in recurrent glioblastoma and expects topline data in mid-2027.
1. Trial enrollment completed
Cerenome completed enrollment in the Phase 2 Respect-GBM trial of Reyobiq in recurrent glioblastoma. The company expects topline data in mid-2027.
